Min.Order / FOB Price:Get Latest Price
500 Gram |
Negotiable |
CAS:148031-34-9 C35H49N11O9S2 Eptifibatide CAS:148031-34-9 C35H49N11O9S2 factory price high purity 99% CAS:148031-34-9 C35H49N11O9S2 technical grade or OLED grade
Eptifibatide Basic information |
Product Name: | Eptifibatide |
Synonyms: | n6-(aminoiminomethyl)-n2-(3-mercapto-1-oxopropyl-l-lysylglycyl-l-a-aspartyl-l-tryptophyl-l-prolyl-l-cysteinamide;INTEGRELIN;EPTIFIBATIDE ACETATE;MAP-LYS-GLY-ASP-TRP-PRO-CYS-NH2;Mpr-Harg-Gly-Asp-Trp-Pro-Cys-NH2,( Disulfide Bridge:1-7);Eptifibatide;Human Eptifibatide;Eptifitide |
CAS: | 148031-34-9 |
MF: | C35H49N11O9S2 |
MW: | 831.96 |
EINECS: | |
Product Categories: | Amino Acid Derivatives;Peptide;proteins |
Mol File: | 148031-34-9.mol |
Eptifibatide Chemical Properties |
CAS DataBase Reference | 148031-34-9(CAS DataBase Reference) |
Safety Information |
Eptifibatide Usage And Synthesis |
Pharmacological effects |
Eptifibatide is a platelet glycoprotein Ⅱb / Ⅲa receptor reversible antagonist,adverse reactions are mild , it can be discontinued immediately while adverse reactions occur . It has Strong effect and high selectivity . It has no antigenicity,and it does not cause allergic reactions. It is used For acute coronary syndrome, coronary intervention before treatment and acute Q-wave myocardial infarction. It can relieve unstable angina symptoms and reduce the incidence of cardiovascular events. It can limit the non-Q-wave myocardial infarction,and reduce through wall myocardial infarction occurrance. Eptifibatide is used to treat acute coronary syndrome, the starting amount is 180μg / kg, the intravenous maintenance dose is per minute 2μg / kg continuous intravenous infusion 72h, if implementing the primary percutaneous coronary intervention, continuous intravenous drip after surgery is 18 ~ 24h. For percutaneous coronary intervention, the starting amount is 180μg / kg intravenous injection, after 2μg / kg continuous intravenous infusion every minute, after 10 min, administrated again with 180μg / kg intravenously per minute , thereafter 2μg / kg continuous intravenous infusion for 18 ~ 24h. |
Eptifibatide |
Eptifibatide is a cyclic heptapeptide, by preventing fibrinogen, von Willebrand factor and other adhesive ligands binding to GPIIb / IIIa , it can reversibly inhibit platelet aggregation. When administrated intravenously, vitro inhibition of platelet aggregation of eptifibatide is in a dose- and concentration-dependent manner. Inhibition of platelet aggregation is reversible after Eptifibatide infusion is stopped , which is believed to be caused by dissociation of eptifibatide and platelet. Platelet membrane glycoprotein (GP) Ⅱb / Ⅲa receptor antagonists: after platelet activation, platelet membrane GP Ⅱb / Ⅲa receptor changes its conformation to bind to the end of fibrinogen dimer to complete platelet aggregation. So, GP Ⅱb / Ⅲa receptor is believed to be the final common pathway of platelet aggregation. platelet GP Ⅱb / Ⅲa receptor antagonist Currently in clinical use, it has the following three types; ① abciximab (Abciximab reopro) is the Fab fragment of a monoclonal antibody of platelet GP Ⅱb / Ⅲa receptor. ②Eptifibatide, Integrilin is a cyclic heptapeptide. ③ tirofiban is a small molecule non-peptide compound. Eptifibatide for injection is a small molecule with heptapeptide containing Lys-Gly-Asp amino acid sequence (KGD), which is like fibrinogen recognizing and binding site GPⅡb / Ⅲa receptors ,it can highly and specially bind to platelets GPⅡb / Ⅲa receptors, it is the GPⅡb / Ⅲa receptor specific competitive inhibitor ,with a low affinity, high dissociation rate, short plasma half-life , platelet aggregation restores baseline levels within 4-8 hours after stopping the infusion . American College of Cardiology (ACC) and the American Heart Association (AHA) guidelines recommend eptifibatide injection can be used for acute coronary syndrome (unstable angina, non-ST-segment elevation myocardial infarction) or supporting through percutaneous coronary intervention (PCI) drug treatment , it is continuous used for 72 hours. Long-term animal studies on the carcinogenic potential of eptifibatide are not made. the Ames test, mouse lymphoma cells (L 5178Y, TK +/-) forward mutation test, the human lymphocyte chromosome aberration assay, or mouse micronucleus test, have shown that eptifibatide is not genotoxic. continuous infusion for a daily dose of the Eptifibatide reaching 72 mg / kg / day (calculated according to body surface area, it is 4 times of the maximum recommended human daily dose), has no effect on fertility and reproductive capacity of male and female rats. The above information is edited by the Chemicalbook of Tian Ye. |
Henan Sunlake Enterprise Corporation is located in Henan Province , The central plain of China , Which enjoys favorable geogeaphical position and convenient transportion. The com[any was established in june. 1998, until now having more than 18 years experience in manufacturing & exporting chemical raw material .
Sunlake is a professional manufacturer engaged in producing and selling chemicals,including Organic & inorganic chemicals , pigments & Dyestuffs , Water treatment chemicals , Food & FEED additives and others. These products have been being well exported to Europe, Southeast Asia, the Middle East ,Africa, South America and some other countries and areas.
We sincerely welcome foreign friends to visit our plant for cooperation. With the idea of "quality first,credit priority, Excellent service", We are highly acknowledged by customers for good quality and competitive price. More importantly , the company has a strong R & D team, who are professional engineers and scholars with Ph. D. .So we are confident to serve you better with our high - quality products and professional team. We are taking great efforts to provide our customers with demanded goods and professional services, and continuously improve our core ability of competition and get the momentum for sustainable development, and finally make us being a reliable and professional supplier in international market.
We welcome any serious inquiries from all customers of the world, and sincerely hope to cooperate with you for a brilliant future!
CAS NO:54735-61-4
CAS NO:3387-36-8
CAS NO:869357-68-6
CAS NO:643-10-7
CAS NO:1420-49-1
CAS NO:14985-44-5
About|Contact|Cas|Product Name|Molecular|Country|Encyclopedia
Message|New Cas|MSDS|Service|Advertisement|CAS DataBase|Article Data|Manufacturers | Chemical Catalog
©2008 LookChem.com,License: ICP
NO.:Zhejiang16009103
complaints:service@lookchem.com Desktop View